Business combination contingent consideration arrangements, percentage payable to consideration rights holders.

No definition available.

Name:	achv_BusinessCombinationContingentConsiderationArrangementsPercentagePayableToConsiderationRightsHolders
Namespace Prefix:	achv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent value rights liability recovery.

+ References

No definition available.

+ Details

Name:	achv_ContingentValueRightsLiabilityRecovery
Namespace Prefix:	achv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of contingent value rights to be issued for each share of common stock outstanding.

+ References

No definition available.

+ Details

Name:	achv_NumberOfContingentValueRightsToBeIssuedForEachShareOfCommonStockOutstanding
Namespace Prefix:	achv_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Period when results of operations of the acquired entity are included in the income statement of the combined entity, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionPeriodResultsIncludedInCombinedEntity1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=84159872&loc=d3e21463-112644

+ Details

Name:	us-gaap_CommonStockSharesOutstanding
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=66048111&loc=d3e19207-110258

+ Details

Name:	us-gaap_FairValueAssumptionsExpectedTerm
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.

+ References

+ Details

Name:	us-gaap_FairValueAssumptionsExpectedVolatilityRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Risk-free interest rate assumption used in valuing an instrument.

+ References

+ Details

Name:	us-gaap_FairValueAssumptionsRiskFreeInterestRate
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Price of a single share of a number of saleable stocks of a company.

+ References

No definition available.

+ Details

Name:	us-gaap_SharePrice
Namespace Prefix:	us-gaap_
Data Type:	num:perShareItemType
Balance Type:	na
Period Type:	instant

- Definition

Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

+ Details

Name:	us-gaap_StockholdersEquityNoteStockSplitConversionRatio1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=achv_OncoGenexPharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=achv_ContingentValueRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FairValueByLiabilityClassAxis=achv_WarrantLiabilityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Reverse Merger - Additional Information (Detail) $ / shares in Units, $ in Thousands				12 Months Ended
	Aug. 17, 2017 USD ($)	Aug. 01, 2017 Right $ / shares shares	Jan. 05, 2015	Dec. 31, 2017 USD ($) shares	Dec. 31, 2016 shares
Business Acquisition [Line Items]
Common stock, shares outstanding \| shares				11,947,932	21,230
Contingent value rights recovery \| $				$ 200
OncoGenex Pharmaceuticals, Inc [Member]
Business Acquisition [Line Items]
Reverse stock split ratio		0.0909	0.0909
Share price		$ 4.62
Common stock, shares outstanding \| shares		2,736,703
Number of contingent value rights to be issued for each share of common stock outstanding \| Right		1
Contingent value rights recovery \| $	$ 200
OncoGenex Pharmaceuticals, Inc [Member] \| Contingent Value Rights [Member]
Business Acquisition [Line Items]
Combined company acquisition period results		5 years
Aggregate consideration distributed to the holders, consideration received percent		80.00%
OncoGenex Pharmaceuticals, Inc [Member] \| Warrant [Member]
Business Acquisition [Line Items]
Share price		$ 4.62
OncoGenex Pharmaceuticals, Inc [Member] \| Warrant [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Volatility rate		90.33%
Risk-free interest rate		1.32%
Expected lives		1 year 10 months 28 days
OncoGenex Pharmaceuticals, Inc [Member] \| Warrant [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Volatility rate		106.08%
Risk-free interest rate		1.53%
Expected lives		3 years 2 months 27 days
OncoGenex Pharmaceuticals, Inc [Member] \| Stock Options [Member]
Business Acquisition [Line Items]
Share price		$ 4.62
OncoGenex Pharmaceuticals, Inc [Member] \| Stock Options [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Volatility rate		97.23%
Risk-free interest rate		1.31%
Expected lives		1 year 9 months 25 days
OncoGenex Pharmaceuticals, Inc [Member] \| Stock Options [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Volatility rate		106.63%
Risk-free interest rate		1.54%
Expected lives		3 years 3 months 22 days